Case Study | January 22, 2013

Cordis Announces Two-Year Results from the STROLL Trial of its SFA SMART Stent

STROLL Clinical Study S.M.A.R.T. Stent Peripheral Artery Disease

January 22, 2013 — Cordis Corporation announced the presentation of the two-year STROLL clinical study results at the Abstracts and Late Breaking Clinical Trials session at ISET 2013. 

William A. Gray, M.D., director of Endovascular Services, Cardiovascular Research Foundation, New York, presented the results of the STROLL study (S.M.A.R.T. Vascular Stent Systems in the TReatment of Obstructive SuperficiaL FemoraL Artery Disease) on behalf of the study investigators. The STROLL study assessed the safety and efficacy of the S.M.A.R.T. Vascular Stent Systems in treating patients with obstructive superficial femoral artery (SFA) disease.

"The two-year data from the pivotal STROLL trial highlight not only the durability of the clinical outcomes such as patency and target lesion revascularization using the S.M.A.R.T. Stent in the femoro-popliteal vessels, but also the associated patient outcomes such as Rutherford classification,” said Gray.

In the study, the average lesion length was 77 mm, 23.6 percent of patients presented with total occlusions and 47 percent of patients were diabetic. Freedom from clinically driven target lesion revascularization (TLR) at two years was 80.3 percent. The 24-month primary patency rate for the S.M.A.R.T. Stent was 74.9 percent by Kaplan Meier estimate. The primary duplex patency rate (PSVR>/=2.5) was 83.5 percent. There were no major adverse events at 30 days after the initial index procedure. There was also a low rate of stent fractures noted at 12 months (2.0 percent) with no additional fractures reported out to 24 months. All stent fractures were Type I, least severe, and there were no incidents of more severe stent fractures (Type II-V).

In addition to the excellent clinical outcomes in the STROLL study, the clinical data showed an improvement in patient outcomes. This included minimal or no signs of PAD in more than 80 percent of patients (as measured using Rutherford-Becker classification), and normal Ankle Brachial Index (ABI) in four of five patients at two years.

“The exceptional two-year results in the STROLL Study confirm the long-term efficacy of the S.M.A.R.T. Vascular Stent Systems in the treatment of peripheral arterial disease (PAD),” said Shlomi Nachman, worldwide president, Cordis Corporation. “Beyond the clinical results, the excellent patient outcomes observed at one year were sustained through the second year. The unique design of the S.M.A.R.T. Vascular Stent contributed to these results and we look forward to continuing to build on its legacy.”

STROLL is a multicenter, non-randomized, single-arm, prospective trial comparing the safety and efficacy of the S.M.A.R.T. Stent with a previously published objective performance goal. Patients ?30 years of age with de novo or restenotic native SFA lesion(s) or total occlusions with length ? 4.0 cm to ? 15.0 cm, and reference vessel diameters of ? 4.0 mm to ? 6.0 mm were included in the study. The 12-month primary patency endpoint was defined as no relevant flow reduction by duplex ultrasonography (DUS) determined by independent core lab, and no interim clinically driven TLR. The primary safety endpoint was 30-day freedom from major adverse events, a composite of all-cause death, index limb amputation and clinically driven TLR. Secondary endpoints cover a variety of morphological, clinical and hemodynamic outcomes. The STROLL Study will follow patients out to three years with mandatory X-Ray and DUS at all key follow-up points.

The STROLL study represents the latest commitment by Cordis to continue its groundbreaking work in the fight against vascular disease. Late last year, the U.S. Food and Drug Administration (FDA) approved the S.M.A.R.T. CONTROL Vascular Stent Systems for use in the superficial femoral artery (SFA) and/or the proximal popliteal artery (PPA). The S.M.A.R.T. Stent, which has been approved for peripheral indication in international markets since 1999, is now the first stent in the United States with both Iliac and SFA indications.

For more information: www.cordis.com

Related Content

News | Cardiovascular Clinical Studies | November 26, 2019
November 26, 2019 — The University of Connecticut (UConn) Department of Kinesiology and Hartford Healthcare have sele
FDA Issues Final Guidance on Live Case Presentations During IDE Clinical Trials
News | Cardiovascular Clinical Studies | July 10, 2019
The U.S. Food and Drug Administration (FDA) issued the final guidance “Live Case Presentations During Investigational...
Veradigm Partners With American College of Cardiology on Next-generation Research Registries
News | Cardiovascular Clinical Studies | July 03, 2019
The American College of Cardiology (ACC) has partnered with Veradigm, an Allscripts business unit, to power the next...
New FDA Proposed Rule Alters Informed Consent for Clinical Studies
News | Cardiovascular Clinical Studies | November 19, 2018
The U.S. Food and Drug Administration (FDA) is proposing to add an exception to informed consent requirements for...
A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development. #SCAI, #SCAI2018

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development.  

Feature | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 – New clinical evidance shows common therapy options for psoriasis (PSO), a chronic inflammatory skin di
Intravenous Drug Use is Causing Rise in Heart Valve Infections, Healthcare Costs. #SCAI, #SCAI2018
News | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 — The opioid drug epidemic is impacting cardiology, with a new study finding the number of patients hosp
Patient Enrollment Completed in U.S. IDE Study of THERMOCOOL SMARTTOUCH SF Catheter
News | Cardiovascular Clinical Studies | March 15, 2018
March 15, 2018 –  Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., who wo
Lexington Begins HeartSentry Clinical Trial
News | Cardiovascular Clinical Studies | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme
Endologix Completes Patient Enrollment in the ELEVATE IDE Clinical Study
News | Cardiovascular Clinical Studies | February 06, 2018
February 6, 2018 – Endologix, a developer and marketer of treatments for aortic disorders, announced the completion o
12-Month Results from Veryan Medical's MIMICS-2 IDE Study Presented at LINC
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s MIMICS
Overlay Init